]>
IRCT20200112046092N1 IRCT 2020-07-11 Kerman University of Medical Sciences The efficacy of the traditional medicine preparation of dodder (Cuscuta campestris Yunck.) and polypody (Polypodium vulgare) in patients with obsessive-compulsive disorde The efficacy of the traditional medicine preparation of dodder (Cuscuta campestris Yunck.) and polypody (Polypodium vulgare) in patients with obsessive-compulsive disorder: A double-blind clinical trial 2020-06-21 anticipated 84 Complete https://irct.ir/trial/45072 interventional Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: This study is a double-blind clinical trial on patients with obsessive-compulsive disorder in outpatients referring to Kerman psychiatric clinics in 2021-23, Blinding description: This study is a double blind clinical trial. In this study, after patient consent was signed, all patients participating in this study and the clinical researcher were not aware of the type of medication given to the patient (herbal or placebo). 3 Obsessive-compulsive disorder. Intervention 1: Intervention group: Herbal drug include Basfaj (Polypodium vulgare) rhizome and aftimon (Cuscuta campestris) The components of the drug are 250 mg tablets (150 mg of Besfaij rhizome powder plus 40 mg of Aftimon aqueous extract, equivalent to 150 mg of Aftimon powder), 55 mg of sucrose and 5 mg of magnesium stearate per tablet). In both groups, fluvoxamine tablets are taken with an average dose of 200 mg daily (100 mg tablets twice a day after meals). In the intervention group, in addition to fluvoxamine tablets, a 250 mg tablet containing the powdered rhizome of Besfaij and Aftimon was received twice a day (in the morning, fasting and at night at bedtime). Intervention 2: Control group: In this group, the drug used is fluvoxamine tablets with an average dose of 200 mg daily (100 mg tablets) twice a day after meals and placebo tablet. The placebo tablet contains 250 mg of cornstarch powder. Yes - There is a plan to make this available What will be shared: The data will be available upon request after publication of the article When: after publication of the article To whom: Researchers working in academic institutions Conditions: The request is reviewed on a case-by-case basis Where to obtain: Refer to the author's email responsible for the article How to obtain: The request will be answered within a maximum of two weeks Comments:
public Behnaz Bakhshi Nejad
Jomhuri Eslami Blvd., Faculty of Traditional Iranian Medicine
Kerman Iran (Islamic Republic of) 7618843883 +98 34 3211 0360 behnaz.bn1984@gmail.com Kerman University of Medical Sciences scientific Behnaz Bakhshi Nejad
Kerman, Jomhuri Eslami Blvd., Faculty of Traditional Iranian Medicine
Kerman Iran (Islamic Republic of) 7618843883 +98 34 3211 0360 behnaz.bn1984@gmail.com Kerman University of Medical Sciences Iran (Islamic Republic of) Age range 18 to 70 years Practicing obsessive compulsive disorder Be treated with Fluvoxamine No alcohol or drugs Lack of physical illnesses such as: diabetes, hypertension, cardiovascular problems A score above 21 on the Yale-Brown-OCS criterion Absence of other psychiatric disorders such as bipolar and psychotic disorders Absence of mental retardation Non-pregnancy and lactation 18 years 70 years Both Drug intolerance Necessity to take psychiatric drugs other than fluvoxamine or to take measures such as ECT F42 Obsessive-compulsive disorder Treatment - Drugs Treatment - Drugs Intervention group: Herbal drug include Basfaj (Polypodium vulgare) rhizome and aftimon (Cuscuta campestris) The components of the drug are 250 mg tablets (150 mg of Besfaij rhizome powder plus 40 mg of Aftimon aqueous extract, equivalent to 150 mg of Aftimon powder), 55 mg of sucrose and 5 mg of magnesium stearate per tablet). In both groups, fluvoxamine tablets are taken with an average dose of 200 mg daily (100 mg tablets twice a day after meals). In the intervention group, in addition to fluvoxamine tablets, a 250 mg tablet containing the powdered rhizome of Besfaij and Aftimon was received twice a day (in the morning, fasting and at night at bedtime). Control group: In this group, the drug used is fluvoxamine tablets with an average dose of 200 mg daily (100 mg tablets) twice a day after meals and placebo tablet. The placebo tablet contains 250 mg of cornstarch powder. Severity of obsessive symptoms. Timepoint: Before starting the treatment and after 4 and 8 weeks of taking the drug, the participants are asked to complete the Yale-Brown questionnaire. Method of measurement: Yale-Brown questionnaire. Quality of life. Timepoint: Before starting the treatment and after 4 and 8 weeks of taking the drug, the participants are asked to complete the quality of life questionnaire. Method of measurement: quality of life questionnaire. Determining the effect of gender on the severity of obsessive symptoms and quality of life in patients with obsessive-compulsive disorders treated with fluvoxamine. Timepoint: Before starting treatment and after 4 to 8 weeks of taking the drug. Method of measurement: WHOQOL-BREF questionnaire and Yale-Brown. Determining the effect of age on the severity of obsessive symptoms and quality of life in patients with obsessive-compulsive disorders treated with fluvoxamine. Timepoint: Before starting treatment and after 4 to 8 weeks of taking the drug. Method of measurement: WHOQOL-BREF questionnaire and Yale-Brown. Determining the effect of education on the severity of obsessive symptoms and quality of life in patients with obsessive-compulsive disorders treated with fluvoxamine. Timepoint: Before starting treatment and after 4 to 8 weeks of taking the drug. Method of measurement: WHOQOL-BREF questionnaire and Yale-Brown. Kerman University of Medical Sciences Approved 2020-04-27 Research Ethics Committee of Kerman University of Medical Sciences Medical University Campus,Haft-Bagh Highway Kerman Kerman Iran (Islamic Republic of)